(NASDAQ:FAT), West Coast-Born Pizza Franchise Continues Expansion in Texas with Round Rock, TX Opening LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., parent company of Round Table Pizza and 17 other restaurant concepts, has announced the opening of its first Round Table Pizza in the Greater Austin area in […]
(NYSE:CTS), LISLE, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) — The Board of Directors of CTS Corporation (NYSE: CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on January 23, 2026, to shareholders of record at the close of business on December 26,
(NASDAQ:ELTX), SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activation Robust immune responses were elicited across
(NASDAQ:HOWL), Novel INDUCER(TM) T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE(TM) molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics,
(NasdaqGM:NRIX), SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders, today announced the presentation of new translational data from its ongoing Phase 1 study of NX-1607, an oral, first-in-class inhibitor of Casitas B-lineage lymphoma proto-oncogene B
(NASDAQ:NXXT), MIAMI, FL, Nov. 07, 2025 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ:NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced preliminary unaudited financial results for October 2025. October 2025 Highlights: Revenue: $7.39 million, up 196% year-over-year from $2.50 million in October 2024 Year-to-date revenue through October reached
(NASDAQ:BHAT), NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — As of the reporting date, the price of gold futures on the New York Commodity Exchange continues to set historical all-time highs, reaching over $4,300 per ounce in October 2025, setting another historical record. Since the beginning of this year, gold prices have achieved over 35
NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — Equiniti (EQ), a leading provider of transfer agent and share ownership services, has named Nicholas (Nick) Nichols as Executive Vice President of the Mutual Funds team. In this role, Nichols will help drive key initiatives across EQ's mutual fund services, driving innovation and service for EQ's valued
(NASDAQ:BCAB), — Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment
— Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing –TK-6302 Clinical Trial Application planned in Q4 2025 for initiation of the Phase 1 ATLAS trial in 2026 SAN FRANCISCO and BERLIN, Nov. 07, 2025 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR)